Schedule 13D ownership disclosure

AXOVANT SCIENCES LTD

Security class unavailable · CUSIP: G0750W104

Event date: 2018-06-05

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
89,285,714
Percent of class
73.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-18-038783
Form type
SC 13D/A
Filer
Sio Gene Therapies Inc.
CIK
CIK 1636050
Filed
Jun 07, 2018
Reporting period
Jun 05, 2018
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub